Abstract
Purpose
The combination of **aozheng decoction with postoperative intravesical instillation has been shown to improve the prognosis of bladder cancer patients and prevent recurrence. However, the mechanisms underlying the efficacy of this herbal formula remain largely unclear. This research aims to identify the important components of **aozheng decoction and explore their anti-bladder cancer effect and mechanism using network pharmacology-based experiments.
Methods
The chemical ingredients of each herb in the **aozheng decoction were collected from the Traditional Chinese Medicine (TCM) database. Network pharmacology was employed to predict the target proteins and pathways of action. Disease databases were utilized to identify target genes associated with bladder cancer. A Protein–Protein Interaction (PPI) network was constructed to illustrate the interaction with intersected target proteins. Key targets were identified using Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) functional enrichment analysis. A compound-target-pathway network was established after molecular docking predictions. In vitro experiments with bladder cancer cell lines were conducted using core chemical components confirmed by ultra-performance liquid chromatography quadrupole time-of-flight mass spectrometry (UPLC-qTOF-MS) to verify the conclusions of network pharmacology.
Results
45 active compounds were extracted, and their relationships with Traditional Chinese Medicines (TCMs) and protein targets were presented, comprising 7 herbs, 45 active compounds, and 557 protein targets. The intersection between potential TCM target genes and bladder cancer-related genes yielded 322 genes. GO and KEGG analyses indicated that these targets may be involved in numerous cancer-related pathways. Molecular docking results showed that candidate compounds except mandenol could form stable conformations with the receptor. In vitro experiments on three bladder cancer cell lines demonstrated that quercetin and two other impressive new compounds, bisdemethoxycurcumin (BDMC) and kumatakenin, significantly promoted cancer cell apoptosis through the B-cell lymphoma 2/Bcl-2-associated X (Bcl-2/BAX) pathway and inhibited proliferation and migration through the glycogen synthase kinase 3 beta (GSK3β)/β-catenin pathway.
Conclusion
By employing network pharmacology and conducting in vitro experiments, the mechanism of **aozheng decoction’s effect against bladder cancer was tentatively elucidated, and its main active ingredients and targets were identified, providing a scientific basis for future research.
Similar content being viewed by others
Introduction
Current evidence suggests that bladder cancer was the 10th most prevalent cancer worldwide in 2020 and the most prevalent malignant tumor of the urinary system, responsible for approximately 17,980 cancer-related deaths in the United States [1]. Smoking has been reported to be the most important risk factor for bladder cancer, followed by exposure to petrochemicals. Additionally, the incidence of this disease shows gender-specific differences, with men having approximately four times higher rates than women [2]. Non-muscle-invasive bladder cancer (NMIBC), which remains confined to the epithelium and lamina propria, accounts for over 70% of newly diagnosed cases, while muscle-invasive bladder cancer (MIBC) constitutes 25% of cases [3]. Patients with early-stage NMIBC commonly undergo transurethral bladder resection, and in some cases, intravesical chemotherapy is recommended. However, two-thirds of patients experience relapse within 5 years of treatment, with this proportion rising to 90% after 15 years [4]. Radical cystectomy is invariably required for MIBC patients due to muscle infiltration of the tumor. Despite the availability of multiple therapies such as chemotherapy, radiotherapy, immunotherapy, and targeted therapy for bladder cancer treatment, approximately 50% of MIBC patients experience metastasis within 2 years [5]. Therefore, further research into potential molecular mechanisms and the design of new strategies to improve the survival of bladder cancer patients is crucial.
In Asia, traditional Chinese medicine (TCM) has been widely accepted as a complementary and alternative form of cancer treatment [6]. It is one of the most popular adjuvant therapies for cancer patients after radical surgery in East Asia, offering distinct advantages, including being multi-component, multi-target, and having minimal side effects due to its natural composition, garnering increased attention worldwide. Both retrospective and prospective studies have demonstrated the therapeutic effect of TCM on cancer [Western blot analysis Cells were digested and lysed with ice-cold RIPA lysis buffer (containing 1 mM PMSF). The mixture was then centrifuged at 4 ℃ for 20 min at 12,000 ×g. The supernatant protein was collected, and the concentration was determined by bicinchoninic acid assay (BCA). Loading buffer was added to the sample in a ratio of 1:4, and the mixture was boiled for 10 min. The same amount of protein (20 µg) on each sample was separated by 4–15% sodium dodecyl sulfate–polyacrylamide gradient gel electrophoresis (SDS-PAGE) and then transferred to the polyvinylidene fluoride (PVDF) membrane through the transfer box. The PVDF membrane was immersed in the prepared 5% skimmed milk and shaken for 1 h. After being washed, the membrane was placed in a box with the appropriate primary antibody at 4 ℃ overnight. After reacting with the secondary antibody for 1 h, the band was exposed and photographed after drop** the develo** solution. All results were expressed as mean ± standard deviation (SD). Fiji (ImageJ) software was used for image analysis. Data were analyzed using GraphPad Prism 9.0.0, and the significance of the difference was analyzed by one-way analysis of variance analysis. Statistical significance was defined as P < 0.05.Statistical analysis
Results
The TCM-compound-target network
45 active compounds in ** with bladder cancer were identified, indicating that this formulation exerts a pharmacological effect on bladder cancer through multiple targets. Quercetin, kumatakenin, polyporusterone G, BDMC, and mandenol were identified as the top five important active compounds. Quercetin is a type of flavonoid with multiple biological activities widely distributed in the plant kingdom. It has been shown to induce apoptosis of bladder cancer cells through the AMPK pathway [29] and yield a sensitizing effect for bladder cancer radiotherapy [30]. Kumatakenin is a natural product first documented in clove, which could induce apoptosis of ovarian cancer cells and inhibit the expression of M2 markers to regulate the tumor microenvironment [31]. Polyporusterone G, a compound belonging to the family of compounds found in Polyporus umbellatus, has been recognized for its cytotoxic properties on leukemia cell proliferation [32]. Besides, Polyporus umbellatus has been shown to promote apoptosis by downregulating AKT in breast cancer [33]. BDMC, a lipid-soluble polyphenolic curcuminoid, yields a range of biological activities, including cytotoxicity in various human cancer cell types, and is more stable than curcumin [34, 35]. Mandenol has been identified as a long-chain fatty acid ethyl ester that acts as a plant metabolite and an anti-inflammatory agent to combat cancer cells [36]. In short, **aozheng decoction is a multi-component prescription with multi-target efficacy, and the relationship between these agents and bladder cancer warrants further investigation.
Five hub target proteins and their related pathways involved in bladder cancer were screened from the compound-target-pathway network analysis. Among these hub targets, ESR1 emerged as the most significant one. Several studies have validated the essential role of ESR1 in bladder cancer risk stratification [37, 38], especially at the tumor grade level [39], though this cancer is not typically regarded as hormone-related. However, upon conducting molecular docking experiments, the affinity of ESR1 was found to be less than ideal, leading us to discontinue further validation for this target. Similarly, the progesterone receptor (PGR), another hormone-related target, was not considered for further validation due to the minimal expression of this protein in bladder cancer [39, 40].
Consistent with the KEGG pathway analysis results, our hub targets showed significant involvement of MAPK signaling-related proteins, particularly MAPK1 and RAF1. The MAPK signaling pathway is a three-tiered signaling cascade composed of RAF, MEK, and ERK, which are serine/threonine-specific kinases that regulate critical cellular processes, such as cell proliferation, differentiation, and migration [41,42,43]. Based on the pharmacological effects observed when blocking RAF1, it is suggested that quercetin and BDMC, derived from **aozheng decoction, may play a crucial role in inhibiting RAF1/MAPK-dependent malignant biological behavior in bladder cancer cells. Both quercetin and BDMC displayed cytotoxic effects in all three bladder cancer cell lines, as demonstrated by the CCK8 assay. Furthermore, BDMC induced cell apoptosis in a dose-dependent manner and exhibited inhibitory effects on colony formation and cell invasion. Another significant target of interest is CDK2, a member of the serine/threonine protein kinases family involved in cell cycle regulation, crucial for driving cell progression through the S- and M-phases of the cell cycle [44]. Interestingly, numerous studies have reported that phytotherapy exerts anti-cancer effects via CDK2-mediated pathways. For example, genistein, an isoflavone derived from soy, was found to promote apoptosis induction in T24 cells, associated with G2/M phase cell cycle arrest and CDK2 inhibition through regulation of the ROS-dependent PI3K/Akt signaling pathway [45]. Similarly, licochalcone A demonstrated a similar mechanism of ROS-mediated cell cycle arrest and apoptosis, involving CDK2 blockade [46]. In the present study, during virtual docking analysis of **aozheng decoction compounds, polyporusterone G exhibited the highest binding affinity to CDK2. However, due to the limited accessibility of polyporusterone G, we could not validate the cell cycle arrest effect of this rare compound derived from **aozheng decoction.
GSK3β, another type of serine/threonine protein kinase, was first described as a component of glycogen synthase regulation via its phosphorylation. As a core downstream component of PI3K/Akt [47], GSK3β mediates many biological processes in tumor cells and promotes the development and metastasis of many types of tumors through EMT [48, 49]. One study has demonstrated that GSK3β is involved in the β-catenin/Snail1 pathway to promote the EMT process in bladder cancer [50]. Moreover, targeting GSK3β with 9-ING-41 (a small molecule inhibitor of GSK3β) has been observed to have multiple anti-bladder cancer effects, including cell cycle arrest, autophagy, and apoptosis in bladder cancer cells. Combined with gemcitabine or cisplatin, 9-ING-41 enhanced the growth inhibitory effects [51]. Our study found that kumatakenin and BDMC have huge potential as GSK3β inhibitors, exhibiting effective inhibition of tumor cell growth. Furthermore, these compounds demonstrated the ability to suppress cell migration and invasion. Western blot analysis revealed that kumatakenin and BDMC dose-dependently inhibited the phosphorylation of GSK3β and β-catenin. The impairment of cell invasion ability was mechanistically elucidated by the downregulation of MMP9, MMP2, and vimentin upon treatment with kumatakenin or BDMC through the EMT process. Flow cytometry and Western blot analysis revealed pro-apoptotic effects of GSK3β inhibition, accompanied by downregulation of the Bcl-2/BAX ratio, indicating the induction of apoptosis.
Conclusion
By employing network pharmacology and conducting in vitro experiments, we have gained preliminary insights into the mechanism through which **aozheng decoction exerts its effects against bladder cancer (Fig. 12). Moreover, this approach allowed us to identify the primary active ingredients and their respective targets, establishing a scientific foundation for further research endeavors.
Availability of data and materials
The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article.
References
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
Scosyrev E, Noyes K, Feng C, Messing E. Sex and racial differences in bladder cancer presentation and mortality in the US. Cancer. 2009;115(1):68–74.
Kates M, Date A, Yoshida T, Afzal U, Kanvinde P, Babu T, Sopko NA, Matsui H, Hahn NM, McConkey DJ, et al. Preclinical evaluation of intravesical cisplatin nanoparticles for non-muscle-invasive bladder cancer. Clin Cancer Res. 2017;23(21):6592–601.
Brandau S, Suttmann H. Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement. Biomed Pharmacother. 2007;61(6):299–305.
Knowles MA, Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. 2015;15(1):25–41.
Chen Z, Gu K, Zheng Y, Zheng W, Lu W, Shu XO. The use of complementary and alternative medicine among Chinese women with breast cancer. J Altern Complement Med. 2008;14(8):1049–55.
**ang Y, Guo Z, Zhu P, Chen J, Huang Y. Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science. Cancer Med. 2019;8(5):1958–75.
Chen P, Wu Q, Feng J, Yan L, Sun Y, Liu S, **ang Y, Zhang M, Pan T, Chen X, et al. Erianin, a novel Dibenzyl compound in Dendrobium extract, inhibits lung cancer cell growth and migration via calcium/calmodulin-dependent ferroptosis. Signal Transduct Target Ther. 2020;5(1):51.
Huang S, Chen Y, Pan L, Fei C, Wang N, Chu F, Peng D, Duan X, Wang Y. Exploration of the potential mechanism of Tao Hong Si Wu decoction for the treatment of breast cancer based on network pharmacology and in vitro experimental verification. Front Oncol. 2021;11:731522.
Dong B, Yang Z, Ju Q, Zhu S, Wang Y, Zou H, Sun C, Zhu C. Anticancer effects of Fufang Yiliu Yin formula on colorectal cancer through modulation of the PI3K/Akt pathway and BCL-2 family proteins. Front Cell Dev Biol. 2020;8:704.
Li X, Liu H, Lv C, Du J, Lian F, Zhang S, Wang Z, Zeng Y. Gypenoside-induced apoptosis via the PI3K/AKT/mTOR signaling pathway in bladder cancer. Biomed Res Int. 2022;2022:9304552.
Zhou S, Fan X, Du X, Liu S, Sun H, Zhang Y. Effect of traditional Chinese medicine combined with bladder perfusion with hydroxycamptothecin on color ultrasound and clinical efficacy in patients with bladder cancer surgery. Evid Based Complement Alternat Med. 2021;2021:7178414.
Yang X, Lv H, Jiang W, Zhang J, Hua H. Clinical value analysis of **aozheng decoction combined with bladder perfusion for postoperative treatment of bladder cancer and its effect on serum miR-143 and miR-92a. J Healthc Eng. 2022;2022:8177674.
Ma XP, Cheng C, Zhang ZZ, Ye YQ, Wan GP. Adjunctive treatment of GnRHa combined wenshen xiaozheng decoction in treating endometriosis after laparoscopy: a clinical observation. Zhongguo Zhong ** Yi Jie He Za Zhi. 2014;34(8):922–5.
Chen XZ, Cao ZY, Li JN, Hu HX, Zhang YQ, Huang YM, Liu ZZ, Hu D, Liao LM, Du J. Ethyl acetate extract from Jiedu **aozheng Yin inhibits the proliferation of human hepatocellular carcinoma cells by suppressing polycomb gene product Bmi1 and Wnt/beta-catenin signaling. Oncol Rep. 2014;32(6):2710–8.
Zhang R, Zhu X, Bai H, Ning K. Network pharmacology databases for traditional Chinese medicine: review and assessment. Front Pharmacol. 2019;10:123.
Ru J, Li P, Wang J, Zhou W, Li B, Huang C, Li P, Guo Z, Tao W, Yang Y, et al. TCMSP: a database of systems pharmacology for drug discovery from herbal medicines. J Cheminform. 2014;6:13.
Ji ZL, Zhou H, Wang JF, Han LY, Zheng CJ, Chen YZ. Traditional Chinese medicine information database. J Ethnopharmacol. 2006;103(3):501.
Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 2019;47(W1):W357–64.
Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, Stein TI, Nudel R, Lieder I, Mazor Y, et al. The Genecards suite: from gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics. 2016;54:1.30.31-31.30.33.
Amberger JS, Bocchini CA, Schiettecatte F, Scott AF, Hamosh A. OMIM.org: online Mendelian inheritance in man (OMIM(R)), an online catalog of human genes and genetic disorders. Nucleic Acids Res. 2015;43(Database issue):D789-798.
Wishart DS, Knox C, Guo AC, Shrivastava S, Hassanali M, Stothard P, Chang Z, Woolsey J. DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res. 2006;34(Database issue):D668-672.
Adami BS, Diz FM, Oliveira Goncalves GP, Reghelin CK, Scherer M, Dutra AP, Papaleo RM, de Oliveira JR, Morrone FB, Wieck A, et al. Morphological and mechanical changes induced by quercetin in human T24 bladder cancer cells. Micron. 2021;151:103152.
Shawky S, Makled S, Awaad A, Boraie N. Quercetin loaded cationic solid lipid nanoparticles in a mucoadhesive in situ gel—a novel intravesical therapy tackling bladder cancer. Pharmaceutics. 2022;14(11):2527.
Cheng Z, Ye F, Xu C, Liang Y, Zhang Z, Chen X, Dai X, Ou Y, Mou Z, Li W, et al. The potential mechanism of Longsheyangquan decoction on the treatment of bladder cancer: Systemic network pharmacology and molecular docking. Front Pharmacol. 2022;13:932039.
Zhang LH, Zhang WY, **ong JM, Duan XM, Hai LN, Zhang YL, Zhang MM, Qin GF, Zhang GW. Mechanisms of Compound Kushen Injection for the treatment of bladder cancer based on bioinformatics and network pharmacology with experimental validation. Chin J Nat Med. 2022;20(1):43–53.
Li X, Yu H, Gong Y, Wu P, Feng Q, Liu C. Fuzheng **aozheng prescription relieves rat hepatocellular carcinoma through improving anti-inflammation capacity and regulating lipid related metabolisms. J Ethnopharmacol. 2022;284:114801.
Xu Y, Cai X, Zong B, Feng R, Ji Y, Chen G, Li Z. Qianlie **aozheng decoction induces autophagy in human prostate cancer cells via inhibition of the Akt/mTOR pathway. Front Pharmacol. 2018;9:234.
Su Q, Peng M, Zhang Y, Xu W, Darko KO, Tao T, Huang Y, Tao X, Yang X. Quercetin induces bladder cancer cells apoptosis by activation of AMPK signaling pathway. Am J Cancer Res. 2016;6(2):498–508.
Alban L, Monteiro WF, Diz FM, Miranda GM, Scheid CM, Zotti ER, Morrone FB, Ligabue R. New quercetin-coated titanate nanotubes and their radiosensitization effect on human bladder cancer. Mater Sci Eng C Mater Biol Appl. 2020;110:110662.
Woo JH, Ahn JH, Jang DS, Lee KT, Choi JH. Effect of Kumatakenin isolated from cloves on the apoptosis of cancer cells and the alternative activation of tumor-associated macrophages. J Agric Food Chem. 2017;65(36):7893–9.
Ohsawa T, Yukawa M, Takao C, Murayama M, Bando H. Studies on constituents of fruit body of Polyporus umbellatus and their cytotoxic activity. Chem Pharm Bull. 1992;40(1):143–7.
Tan XL, Guo L, Wang GH. Polyporus umbellatus inhibited tumor cell proliferation and promoted tumor cell apoptosis by down-regulating AKT in breast cancer. Biomed Pharmacother. 2016;83:526–35.
Ma YS, Peng SF, Wu RS, Chueh FS, Huang WW, Chen PY, Kuo CL, Huang AC, Liao CL, Hsia TC. Bisdemethoxycurcumin suppresses human osteosarcoma U-2 OS cell migration and invasion via affecting the PI3K/Akt/NF-kappaB, PI3K/Akt/GSK3beta and MAPK signaling pathways in vitro. Oncol Rep. 2022;48(6):210.
Luo C, Du Z, Wei X, Chen G, Fu Z. Bisdemethoxycurcumin attenuates gastric adenocarcinoma growth by inducing mitochondrial dysfunction. Oncol Lett. 2015;9(1):270–4.
Kim H, Kim H, Mosaddik A, Gyawali R, Ahn KS, Cho SK. Induction of apoptosis by ethanolic extract of mango peel and comparative analysis of the chemical constitutes of mango peel and flesh. Food Chem. 2012;133(2):416–22.
Breyer J, Wirtz RM, Laible M, Schlombs K, Erben P, Kriegmair MC, Stoehr R, Eidt S, Denzinger S, Burger M, et al. ESR1, ERBB2, and Ki67 mRNA expression predicts stage and grade of non-muscle-invasive bladder carcinoma (NMIBC). Virchows Arch. 2016;469(5):547–52.
Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, et al. Prognostic value of molecular breast cancer subtypes based on Her2, ESR1, PGR and Ki67 mRNA-expression in muscle invasive bladder cancer. Transl Oncol. 2018;11(2):467–76.
Imai Y, Noda S, Matsuyama C, Shimizu A, Kamai T. Sex steroid hormone receptors in bladder cancer: Usefulness in differential diagnosis and implications in histogenesis of bladder cancer. Urol Oncol. 2019;37(6):353.e9-353.e15.
Erben P, Sikic D, Wirtz RM, Martini T, Weis CA, Breyer J, Otto W, Keck B, Hartmann A, Bolenz C, et al. Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder. Virchows Arch. 2019;474(2):209–17.
Desideri E, Cavallo AL, Baccarini M. Alike but different: RAF paralogs and their signaling outputs. Cell. 2015;161(5):967–70.
Durrant DE, Morrison DK. Targeting the RAF kinases in human cancer: the RAF dimer dilemma. Br J Cancer. 2018;118(1):3–8.
Drosten M, Barbacid M. Targeting the MAPK pathway in KRAS-driven tumors. Cancer Cell. 2020;37(4):543–50.
Tadesse S, Caldon EC, Tilley W, Wang S. Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update. J Med Chem. 2019;62(9):4233–51.
Park C, Cha HJ, Lee H, Hwang-Bo H, Ji SY, Kim MY, Hong SH, Jeong JW, Han MH, Choi SH, et al. Induction of G2/M cell cycle arrest and apoptosis by genistein in human bladder cancer T24 cells through inhibition of the ROS-dependent PI3k/Akt signal transduction pathway. Antioxidants. 2019;8(9):327.
Hong SH, Cha HJ, Hwang-Bo H, Kim MY, Kim SY, Ji SY, Cheong J, Park C, Lee H, Kim GY, et al. Anti-proliferative and pro-apoptotic effects of licochalcone a through ROS-mediated cell cycle arrest and apoptosis in human bladder cancer cells. Int J Mol Sci. 2019;20(15):3820.
Song M, Bode AM, Dong Z, Lee MH. AKT as a therapeutic target for cancer. Cancer Res. 2019;79(6):1019–31.
Hu P, Zong B, Chen Q, Shao R, Chen M, Yang Y, Shao G. Microtubule-associated protein 4 promotes epithelial mesenchymal transition in hepatocellular cancer cells via regulating GSK3beta/beta-catenin pathway. Heliyon. 2023;9(3):e14309.
Balamurugan K, Poria DK, Sehareen SW, Krishnamurthy S, Tang W, McKennett L, Padmanaban V, Czarra K, Ewald AJ, Ueno NT, et al. Stabilization of E-cadherin adhesions by COX-2/GSK3beta signaling is a targetable pathway in metastatic breast cancer. JCI Insight. 2023;8(6):e156057.
Zhou Z, Liu X, Li Y, Li J, Deng W, Zhong J, Chen L, Li Y, Zeng X, Wang G, et al. TP53INP2 modulates epithelial-to-mesenchymal transition via the GSK-3beta/beta-catenin/snail1 pathway in bladder cancer cells. Onco Targets Ther. 2020;13:9587–97.
Kuroki H, Anraku T, Kazama A, Bilim V, Tasaki M, Schmitt D, Mazar AP, Giles FJ, Ugolkov A, Tomita Y. 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019;9(1):19977.
Acknowledgements
The authors pay tribute to all the care and support that has gone into the research. We thank Home for Researchers editorial team (www.home-for-researchers.com) for language editing service.
Funding
This study was supported by the National Natural Science Foundation of China (82072821 and 92059112) and Shanghai Songjiang Municipal Science and Technology Commission Natural Science Foundation (20SJKJGG250).
Author information
Authors and Affiliations
Contributions
BS conceived the study and designed the experiments. BS and FZ provided funding for the study and revised the manuscript. JMZ and JHM performed the research and data analysis and wrote the first draft of the manuscript. ZNH completed part of the experiment. YLY revised the paper. ZYW, XQC, and CKY contributed to the analysis and interpretation of data. All authors read and approved the final manuscript for publication.
Corresponding authors
Ethics declarations
Competing interests
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Zhuang, J., Mo, J., Huang, Z. et al. Mechanisms of **aozheng decoction for anti-bladder cancer effects via affecting the GSK3β/β-catenin signaling pathways: a network pharmacology-directed experimental investigation. Chin Med 18, 104 (2023). https://doi.org/10.1186/s13020-023-00818-5
Received:
Accepted:
Published:
DOI: https://doi.org/10.1186/s13020-023-00818-5